Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease episode artwork

EPISODE · Jul 29, 2025 · 19 MIN

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

from touchPODCAST · host touchpodcast

touchEXPERT FOCUS for touchNEUROLOGY and touchCARDIO Listen to Dr Chafic Karam share expert insights on diagnosing and managing ATTRv amyloidosis. In this short interview, he covers red-flag symptoms, diagnostic challenges and key strategies for differentiating ATTRv. He also discusses current treatment options, including TTR stabilisers and gene silencers, as well as emerging therapies aimed at improving patient outcomes. The expert: Dr Chafic Karam, University of Pennsylvania, Philadelphia, PA, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our websites:  https://touchneurology.com/ and https://touchcardio.com/

Episode metadata supplied by the publisher feed · Published Jul 29, 2025

Embed this episode

Ready to play

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

0:00 19:06

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 19 minutes long.

When was this touchPODCAST episode published?

This episode was published on July 29, 2025.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!